JPMorgan analyst Tessa Romero kept a Neutral rating with no price target on Prime Medicine (PRME) following a transfer of coverage. The firm says it would consider recommending the shares as the company moves closer to “value-creating milestones.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRME:
- Cautious Hold Rating for Prime Medicine, Inc. Amid Promising Preclinical Results and Extended Development Timeline
- Prime Medicine’s Promising Advances in Gene Editing Justify Buy Rating
- Prime Medicine price target lowered to $4.25 from $5 at Citi
- Prime Medicine Advances Genetic Therapy Pipeline in Q3 2025
- Prime Medicine files automatic mixed securities shelf